Efficacy and Safety of Dabigatran Dual Therapy vs Warfarin Triple Therapy in Atrial Fibrillation After PCI in Relation to Time in Therapeutic Range: A Subgroup Analysis From the RE-DUAL PCI Trial.

被引：0

作者：

Lip, Gregory Y. H. ^{[1
]}

Bhatt, Deepak L. ^{[2
]}

Hohnloser, Stefan H. ^{[3
]}

Kimura, Takeshi ^{[4
]}

Meide, Corinna ^{[5
]}

Nordaby, Matias ^{[6
]}

Oldgren, Jonas ^{[7
,8
]}

Steg, Philippe G. ^{[9
]}

ten Berg, Jurrien M. ^{[10
]}

Cannon, Christopher ^{[11
]}

机构：

[1] Univ Birmingham, Inst Cardiovasc Sci, Birmingham, W Midlands, England

[2] Harvard Med Sch, Brigham & Womens Hosp, Heart & Vasc Ctr, Boston, MA 02115 USA

[3] Goethe Univ Frankfurt, Div Cardiol, Dept Med, Frankfurt, Germany

[4] Kyoto Univ, Dept Cardiovasc Med, Kyoto, Japan

[5] HMS Analyt Software GmbH, Analyt Software, Weimar, Lahn, Germany

[6] Boehringer Ingelheim Int GmbH, TA CardioMetab, Ingelheim, Germany

[7] Uppsala Univ, Uppsala Clin Rsch Ctr, Uppsala, Sweden

[8] Uppsala Univ, Dept Med Sci, Uppsala, Sweden

[9] Hop Bichat Claude Bernard, AP HP, Dept Cardiol, Paris, France

[10] St Antonius Hosp, Cardiol, Nieuwegein, Netherlands

[11] Brigham & Womens Hosp, Test, 75 Francis St, Boston, MA 02115 USA

来源：

CIRCULATION | 2018年 / 138卷

关键词：

Antithrombotic therapy; Atrial fibrillation; Coronary artery disease; Dabigatran; Percutaneous coronary intervention (PCI);

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A11383

引用

页数：3

共 50 条

[1] The effect of PCI complexity on the efficacy and safety of dabigatran dual therapy vs warfarin triple therapy in atrial fibrillation: a subgroup analysis from the RE-DUAL PCI trial
Mauri, L.
Steg, P. S.
Bhatt, D. L.
Hohnloser, S. H.
Nordaby, M.
Miede, C.
Kimura, T.
Lip, G. Y. H.
Oldgren, J.
Ten Berg, J. M.
Cannon, C.
EUROPEAN HEART JOURNAL, 2018, 39 : 653 - 653
[2] Dual antithrombotic therapy with dabigatran vs triple therapy with warfarin after PCI in patients with atrial fibrillation and diabetes mellitus (a RE-DUAL PCI subgroup analysis)
Maeng, M.
Steg, P. G.
Bhatt, D. L.
Hohnloser, S. H.
Nordaby, M.
Miede, C.
Kimura, T.
Lip, G. Y. H.
Oldgren, J.
Ten Berg, J. M.
Cannon, C. P.
EUROPEAN HEART JOURNAL, 2018, 39 : 1090 - 1091
[3] The effect of age on the efficacy and safety of dabigatran dual therapy in atrial fibrillation after PCI: a subgroup analysis from the RE-DUAL PCI trial
Ten Berg, J. M.
Steg, P. G.
Bhatt, D. L.
Hohnloser, S. H.
De Veer, A. N. N. E.
Nordaby, M.
Miede, C.
Kimura, T.
Lip, G. Y. H.
Oldgren, J.
Cannon, C. P.
EUROPEAN HEART JOURNAL, 2018, 39 : 439 - 440
[4] The effect of sex on the efficacy and safety of dabigatran dual therapy in atrial fibrillation after PCI: a subgroup analysis from the RE-DUAL PCI trial
Eccleston, D.
Ten Berg, J. M.
Steg, P. G.
Bhatt, D. L.
Hohnloser, S. H.
De Veer, A.
Nordaby, M.
Miede, C.
Kimura, T.
Lip, G. Y. H.
Oldgren, J.
Cannon, C. P.
EUROPEAN HEART JOURNAL, 2020, 41 : 33 - 34
[5] DUAL ANTITHROMBOTIC THERAPY WITH DABIGATRAN VERSUS TRIPLE THERAPY WITH WARFARIN AFTER PCI IN PATIENTS WITH ATRIAL FIBRILLATION AND DIABETES MELLITUS (A RE-DUAL PCI™ SUBGROUP ANALYSIS)
Ruggieri, G.
EUROPEAN HEART JOURNAL SUPPLEMENTS, 2019, 21 (0E) : E114 - E115
[6] The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials)
Eccleston, David S.
Kim, Joseph M.
ten Berg, Jurien M.
Steg, P. Gabriel
Bhatt, Deepak L.
Hohnloser, Stefan H.
de Veer, Anne
Nordaby, Matias
Miede, Corinna
Kimura, Takeshi
Lip, Gregory Y. H.
Oldgren, Jonas
Cannon, Christopher P.
CLINICAL CARDIOLOGY, 2021, 44 (07) : 1002 - 1010
[7] RELATION OF STROKE AND BLEEDING RISK PROFILES TO EFFICACY AND SAFETY OF DABIGATRAN IN ATRIAL FIBRILLATION AFTER PCI: AN ANCILLARY ANALYSIS FROM THE RE-DUAL PCI TRIAL
Lip, Gregory
Mauri, Laura
Montalescot, Gilles
Ozkor, Mick
Vardas, Panagiotis
Steg, Philippe Gabriel
Bhatt, Deepak
Hohnloser, Stefan
Kleine, Eva
Nordaby, Matias
Kimura, Takeshi
Oldgren, Jonas
Ten Berg, Jurrien
Cannon, Christopher
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 289 - 289
[8] Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial
Lip, Gregory Y. H.
Mauri, Laura
Montalescot, Gilles
Ozkor, Mick
Vardas, Panagiotis
Steg, Philippe Gabriel
Bhatt, Deepak L.
Hohnloser, Stefan H.
Miede, Corinna
Nordaby, Matias
Brueckmann, Martina
Kreuzer, Joerg
Kimura, Takeshi
Oldgren, Jonas
ten Berg, Jurrien M.
Cannon, Christopher P.
AMERICAN HEART JOURNAL, 2019, 212 : 13 - 22
[9] Subgroup Analysis From the RE-DUAL PCI Trial: Dual Antithrombotic Therapy With Dabigatran in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
Oldgren, Jonas
Steg, Philippe-Gabriel
Hohnloser, Stefan H.
Lip, Gregory Y.
Ellis, Stephen G.
Kimura, Takeshi
Nordaby, Matias
ten Berg, Jurrien M.
Bhatt, Deepak L.
Cannon, Christopher P.
Kleine, Eva
CIRCULATION, 2017, 136 (24) : E457 - E457
[10] Dual Antithrombotic Therapy With Dabigatran vs Triple Therapy With Warfarin After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation With or Without a Proton Pump Inhibitor (A Prospectively Defined Subgroup Analysis in the RE-DUAL PCI Randomized Trial).
Nicolau, Jose C.
Bhatt, Deepak L.
Hohnloser, Stefan H.
Kimura, Takeshi
Lip, Gregory Y.
Meide, Corinna
Nordaby, Matias
Oldgren, Jonas
Steg, Philippe
ten Berg, Jurrien M.
Cannon, Christopher
CIRCULATION, 2018, 138

← 1 2 3 4 5 →